BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 30287880)

  • 21. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.
    Horn H; Ziepert M; Becher C; Barth TF; Bernd HW; Feller AC; Klapper W; Hummel M; Stein H; Hansmann ML; Schmelter C; Möller P; Cogliatti S; Pfreundschuh M; Schmitz N; Trümper L; Siebert R; Loeffler M; Rosenwald A; Ott G;
    Blood; 2013 Mar; 121(12):2253-63. PubMed ID: 23335369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab.
    Perry AM; Alvarado-Bernal Y; Laurini JA; Smith LM; Slack GW; Tan KL; Sehn LH; Fu K; Aoun P; Greiner TC; Chan WC; Bierman PJ; Bociek RG; Armitage JO; Vose JM; Gascoyne RD; Weisenburger DD
    Br J Haematol; 2014 May; 165(3):382-91. PubMed ID: 24506200
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic Significance of
    Rosenwald A; Bens S; Advani R; Barrans S; Copie-Bergman C; Elsensohn MH; Natkunam Y; Calaminici M; Sander B; Baia M; Smith A; Painter D; Pham L; Zhao S; Ziepert M; Jordanova ES; Molina TJ; Kersten MJ; Kimby E; Klapper W; Raemaekers J; Schmitz N; Jardin F; Stevens WBC; Hoster E; Hagenbeek A; Gribben JG; Siebert R; Gascoyne RD; Scott DW; Gaulard P; Salles G; Burton C; de Jong D; Sehn LH; Maucort-Boulch D
    J Clin Oncol; 2019 Dec; 37(35):3359-3368. PubMed ID: 31498031
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy.
    Savage KJ; Johnson NA; Ben-Neriah S; Connors JM; Sehn LH; Farinha P; Horsman DE; Gascoyne RD
    Blood; 2009 Oct; 114(17):3533-7. PubMed ID: 19704118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Prognostic significance of proteins expression by immunohistochemical method in diffuse large B cell lymphoma].
    Yu WJ; Cao LH; Wang JH; Wang ZM; Qian WB; Tong HY; Meng HT; Mai WY; Mao LP; Qian JJ; Jin J
    Zhonghua Xue Ye Xue Za Zhi; 2017 Sep; 38(9):784-788. PubMed ID: 29081196
    [No Abstract]   [Full Text] [Related]  

  • 26. Inferior survival in high-grade B-cell lymphoma with
    McPhail ED; Maurer MJ; Macon WR; Feldman AL; Kurtin PJ; Ketterling RP; Vaidya R; Cerhan JR; Ansell SM; Porrata LF; Nowakowski GS; Witzig TE; Habermann TM
    Haematologica; 2018 Nov; 103(11):1899-1907. PubMed ID: 29903764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic Significance of BCL-2 and BCL-6 Expression in MYC-positive DLBCL.
    Li L; Zhang X; Zhang T; Song Z; Hu G; Li W; Li L; Qiu L; Qian Z; Zhou S; Liu X; Feng L; Pan Y; Zhai Q; Meng B; Ren X; Fu K; Wang P; Wang X; Zhang H
    Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):e381-e389. PubMed ID: 29983382
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of
    Qin Y; Chen H; Liu P; Zhang C; Yang J; Gui L; He X; Zhou L; Zhou S; Jiang S; Jiang H; Shi Y
    Cancer Biol Med; 2021 Nov; 19(6):893-909. PubMed ID: 34806851
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
    Xu-Monette ZY; Dabaja BS; Wang X; Tu M; Manyam GC; Tzankov A; Xia Y; Zhang L; Sun R; Visco C; Dybkaer K; Yin L; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Zhao X; Winter JN; Piris MA; McDonnell TJ; Miranda RN; Li Y; Medeiros LJ; Young KH
    Mod Pathol; 2015 Dec; 28(12):1555-73. PubMed ID: 26541272
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinicopathologic and Prognostic Significance of Bruton's Tyrosine Kinase Expression in Diffuse Large B-Cell Lymphoma.
    Han YB; Yang JM; Kwon HJ; Lee JO; Lee JS; Paik JH
    Anticancer Res; 2021 Nov; 41(11):5677-5692. PubMed ID: 34732441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.
    Xu-Monette ZY; Møller MB; Tzankov A; Montes-Moreno S; Hu W; Manyam GC; Kristensen L; Fan L; Visco C; Dybkaer K; Chiu A; Tam W; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huang Q; Huh J; Ai W; Ponzoni M; Ferreri AJ; Wu L; Zhao X; Bueso-Ramos CE; Wang SA; Go RS; Li Y; Winter JN; Piris MA; Medeiros LJ; Young KH
    Blood; 2013 Oct; 122(15):2630-40. PubMed ID: 23982177
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma.
    Xu-Monette ZY; Deng Q; Manyam GC; Tzankov A; Li L; Xia Y; Wang XX; Zou D; Visco C; Dybkær K; Li J; Zhang L; Liang H; Montes-Moreno S; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Møller MB; Wang SA; Miranda RN; Piris MA; Winter JN; Medeiros LJ; Li Y; Young KH
    Clin Cancer Res; 2016 Jul; 22(14):3593-605. PubMed ID: 26927665
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).
    Mounier N; Briere J; Gisselbrecht C; Emile JF; Lederlin P; Sebban C; Berger F; Bosly A; Morel P; Tilly H; Bouabdallah R; Reyes F; Gaulard P; Coiffier B
    Blood; 2003 Jun; 101(11):4279-84. PubMed ID: 12576316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup.
    Jiang S; Qin Y; Jiang H; Liu B; Shi J; Meng F; Liu P; Yang J; Yang S; He X; Zhou S; Gui L; Liu H; Lin J; Han-Zhang H; Shi Y
    Int J Cancer; 2020 Nov; 147(9):2611-2620. PubMed ID: 32399964
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.
    Iqbal J; Meyer PN; Smith LM; Johnson NA; Vose JM; Greiner TC; Connors JM; Staudt LM; Rimsza L; Jaffe E; Rosenwald A; Ott G; Delabie J; Campo E; Braziel RM; Cook JR; Tubbs RR; Gascoyne RD; Armitage JO; Weisenburger DD; Chan WC
    Clin Cancer Res; 2011 Dec; 17(24):7785-95. PubMed ID: 21933893
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study.
    Jardin F; Jais JP; Molina TJ; Parmentier F; Picquenot JM; Ruminy P; Tilly H; Bastard C; Salles GA; Feugier P; Thieblemont C; Gisselbrecht C; de Reynies A; Coiffier B; Haioun C; Leroy K
    Blood; 2010 Aug; 116(7):1092-104. PubMed ID: 20435884
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
    Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
    J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
    [TBL] [Abstract][Full Text] [Related]  

  • 38. P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma.
    Wang XJ; L Jeffrey Medeiros ; Bueso-Ramos CE; Tang G; Wang S; Oki Y; Desai P; Khoury JD; Miranda RN; Tang Z; Reddy N; Li S
    Mod Pathol; 2017 Feb; 30(2):194-203. PubMed ID: 27739436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. p53 expression in large B-cell lymphomas with MYC extra copies and CD99 expression in large B-cell lymphomas in relation to MYC status.
    Richardson AI; Zhang D; Woodroof J; Cui W
    Hum Pathol; 2019 Apr; 86():21-31. PubMed ID: 30496802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence and clinicopathologic features of CD30-positive de novo diffuse large B-cell lymphoma in Chinese patients: a retrospective study of 232 cases.
    Gong QX; Lu TX; Liu C; Wang Z; Liang JH; Xu W; Li JY; Zhang ZH; Chen Q
    Int J Clin Exp Pathol; 2015; 8(12):15825-35. PubMed ID: 26884853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.